Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-13


Brief Information

Target Synonym:Interleukin-13,IL13,Interleukin 13,IL-13,Bronchial Hyperresponsiveness-1 (Bronchial Asthma),Allergic Rhinitis,P600,NC30,MGC116789,MGC116788,BHR1,MGC116786,ALRH
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IL3-H52H4-Cell-based assay

Human IL-13 Protein, His Tag, premium grade (Cat. No. IL3-H52H4) stimulates proliferation of TF-1 cells. The EC50 for this effect is 0.05-0.08 μg/mL (Routinely tested).

 IL-13 SPR

Biotinylated Human IL-13 R alpha 1 Protein, His,Avitag (Cat. No. IL1-H82E8) captured on Biotin CAP-Series S Sensor Chip can bind Human IL-13 Protein, His Tag, premium grade (Cat. No. IL3-H52H4) with an affinity constant of 34.4 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

 IL-13 BLI

Loaded Biotinylated Human IL-13, His,Avitag (Cat. No. IL3-H82E5) on SA Biosensor, can bind Human IL-13 R alpha 2, His Tag (Cat. No. IL2-H52H5) with an affinity constant of 6.31 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name



Interleukin 13 (IL13) is also known as ALRH, BHR1and P600, is a single-chain glycosylated polypeptide, and is a cytokine critical in regulating inflammatory and immune responses. IL13 is secreted by many cell types, but especially by T helper type 2 (Th2) cells. IL-13 induces its effects through a multi-subunit receptor that includes the alpha chain of the IL-4 receptor (IL-4Rα) and at least one of two known IL-13-specific binding chains. The functions of IL-13 overlap considerably with those of IL-4, especially with regard to changes induced on hematopoietic cells, but these effects are probably less important given the more potent role of IL-4. IL-13 induces matrix metalloproteinases (MMPs) as part of a mechanism that protects against excessive allergic inflammation that predisposes to asphyxiation. IL-13 induces many features of allergic lung disease, including airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion, which all contribute to airway obstruction.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Berdazimer sodium-SB-206 (Novan) NVN-1000-SB-206-Novan; MAP3-NONOate - SB-206; NVN1000-SB206; SB-206; SB-019; NI-MC101 Approved Novan Inc Zelsuvmi, ZELSUVMI, KINSOLUSTM United States Molluscum Contagiosum Lnhc Inc 2024-01-05 Acne Vulgaris; Tinea Pedis; Psoriasis; Molluscum Contagiosum; Condylomata Acuminata; Dermatitis, Atopic Details
Lebrikizumab RO-4909832; PRO-301444; DRM-06; Anti-IL-13; TNX-650; RG-3637; RO-5490255; MILR-1444A; R-3637; DRM 06; LY 3650150; MILR1444A; MILR1444Ab; RG 3637; RO 5490255; TNX 650 Approved Tanox Inc EBGLYSS EU Dermatitis, Atopic Almirall Sa 2023-11-16 Idiopathic Pulmonary Fibrosis; Hodgkin Disease; Skin Diseases; Dermatitis; Asthma; Sinusitis; Alzheimer Disease; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic; Eczema; Skin Diseases, Genetic Details
Tralokinumab BAK-502G9; CAT-354 Approved Medimmune Llc Adtralza, ADBRY EU Dermatitis, Atopic Leo Pharma A/S 2021-06-17 Idiopathic Pulmonary Fibrosis; Colitis, Ulcerative; Asthma; Dermatitis, Atopic; Eczema Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Berdazimer sodium-SB-204 (Novan) MAP3-NONOate-SB-204; NVN1000-SB204; SB-204 Phase 3 Clinical University Of North Carolina At Chapel Hill Acne Vulgaris Details
Cendakimab RPC-4046; ABT-308; CC-93538 Phase 3 Clinical Abbott Laboratories Eosinophilic gastroenteritis (EG); Eosinophilic Esophagitis; Asthma; Dermatitis, Atopic; Eczema Details
Eblasakimab MK-6105; ASLAN-004; CSL-334 Phase 2 Clinical Csl Ltd, Merck Sharp & Dohme Corp Dermatitis, Atopic; Hypersensitivity Details
Dectrekumab/VAK-694 QBX-258 Phase 2 Clinical Novartis Pharma Ag Lymphedema; Asthma Details
PF-07264660 PF-07264660 Phase 2 Clinical Pfizer Inc Dermatitis, Atopic Details
PF-07275315 PF-07275315 Phase 2 Clinical Pfizer Inc Dermatitis, Atopic Details
Lunsekimig SAR-443765 Phase 2 Clinical Sanofi Asthma; Inflammation Details
APG-777 APG777; APG-777; PR004; PR-004 Phase 1 Clinical Apogee Therapeutics Inc Asthma; Dermatitis, Atopic Details
SAR-443726 SAR-443726 Phase 1 Clinical Sanofi Dermatitis, Atopic Details
BD-9 BD-9 Biolojic Design Inc Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message